Clinical Trials Logo

Clinical Trial Summary

A growing body of evidence suggests a wide range of brain areas including medial prefrontal cortex (mPFC), dorsolateral prefrontal cortex (DLPFC) and other subcortical regions, such as anterior cingulate cortex (ACC) are critical for regulating cognitive control over decisions and involving in drug related cue processing. Previous studies have demonstrated that transcranial magnetic stimulation (rTMS) over dorsolateral prefrontal cortex reduces craving for meth dependences. Specifically, the H7 coil induces a magnetic field can target mPFC and ACC. In this study, the investigators investigated whether repeated dTMS intervention of medial prefrontal and cingulate cortices in methamphetamine addiction could reduce the subjective craving and improve the cognitive abilities.


Clinical Trial Description

The study will be conducted at the drug rehabilitation center in China. The whole procedure includes enrollment, pre-intervention evaluation, intervention (for 3 weeks, 5 times a week, 15 times in total), post-intervention evaluation and one month follow up evaluation. In enrollment session, participants are recruited according to inclusion criteria. In the pre-intervention evaluation, firstly, participants need complete a questionnaire to assess their demographic information, drug addiction history and drug abstinence. And then are assigned to either 10Hz group or sham group according to the counterbalance of their basic demographic and drug use information. Then, participants need complete craving, cognitive ability and electroencephalogram (EEG) assessment. For craving assessing, participants are shown a video of methamphetamine usage for 5 minutes, and then rated on the visual analogue scale (0 means completely undesired and 100 means extremely wanting) to report their craving for methamphetamine. For cognitive ability and EEG signal assessing, the whole process is conducted on the computer according to instructions. In the intervention session, dTMS was administered using a TMS stimulator (Magstim, U.K.) equipped with a unique H-shaped coil design. The H-coil version used in this study was the H7 (Brainsway, Jerusalem, Israel). When placed 4-5 cm anterior to the foot motor cortex and used at 100% of the leg resting motor threshold (RMT), the H7 coil stimulates the dorsal mPFC and ACC bilaterally. A participant's RMT was determined before the first treatment and at the beginning of each week by ascertaining the coil position that elicited the minimal involuntary contractions of the feet (three of six attempts). The 10Hz group received 10 Hz dTMS at 100% of RMT, with 3-second pulse and 17-second intervals, for a total of 50 trains and 1500 pulses per session. The sham group received treatment with identical technical parameters, which induced scalp sensations but without penetration of the electric field into the brain. Post-intervention evaluation and one month follow up evaluation are the same as in pre-intervention evaluation. To ensure study quality, some measures are taken as bellow: Researchers and drug rehabilitation staff will work together in whole process and the data will be converted into electronic versions once finishing each evaluation. In the intervention, patients, operators, and raters were blind to treatment condition. Each patient is assigned a magnetic card that determined the coil (real or sham) in the helmet and raters are not present while treatments are administered. After each treatment times, any side effect from participant's report are recorded to assure the safety and feasibility. Statistical analyses are performed using SPSS 21.0. The principal statistical analysis is performed using repeated-measures analysis of variance and regression analysis. All missing data will be recorded and marked. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04202926
Study type Interventional
Source Shanghai Mental Health Center
Contact
Status Completed
Phase N/A
Start date December 30, 2019
Completion date October 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT04449055 - Pilot TMS for Methamphetamine Use Disorder N/A
Completed NCT06288997 - tACS Intervention for Methamphetamine Addiction N/A
Recruiting NCT05162391 - Inflammation in Methamphetamine and STIs (IMSTI) N/A
Completed NCT03336866 - Study of Antibody for Methamphetamine Outpatient Therapy Phase 1/Phase 2
Not yet recruiting NCT06233799 - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder Phase 3
Not yet recruiting NCT03748875 - The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents N/A
Recruiting NCT03341078 - Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users Phase 2
Active, not recruiting NCT03910608 - Paired Associative Stimulation in Methamphetamine Addiction N/A
Terminated NCT05283304 - Monthly Injectable BUP for MA Use Disorder (MURB) Trial Phase 2
Completed NCT04563962 - Contingency Management for PrEP Adherence and/or Methamphetamine Use N/A
Not yet recruiting NCT05334914 - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals N/A
Active, not recruiting NCT05034874 - Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 Phase 2
Recruiting NCT06027814 - MHealth Incentivized Adherence Plus Patient Navigation N/A
Completed NCT04544124 - Delivering Contingency Management in Outpatient Addiction Treatment N/A
Completed NCT01217970 - Safety Interaction Trial Ibudilast and Methamphetamine Phase 1
Completed NCT03825536 - Effect of Methamphetamine on Residual Latent HIV Disease Study Phase 4
Recruiting NCT03470480 - rTMS for Craving in Methamphetamine Use Disorder N/A
Recruiting NCT05128071 - PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT) Early Phase 1